Molecular Microbiology Research 2024, Vol.14, No.1, 10-19 http://microbescipublisher.com/index.php/mmr 15 This method has achieved significant results in the treatment of refractory intestinal diseases such as Clostridium difficile infection, offering new possibilities for the treatment of certain chronic diseases (Punt et al., 2017). Figure 3 Symbiotic interaction between eubiotic flora and the human body results in the maintenance of homeostasis, regulation, and development of the immune system, hosts nutrition, and colonization resistance (Ogunrinola et al., 2020) However, despite the effectiveness of these microbiome regulation strategies in the treatment of chronic diseases, their efficacy and safety remain controversial. There are significant differences in response between different diseases and individuals, and further research and validation are needed on the long-term effects and safety of their application. Therefore, in practical application, it is necessary to develop reasonable treatment plans based on the specific circumstances of the patient and closely monitor the efficacy and adverse reactions. 3.2 The potential of microbiome-based personalized medicine in the treatment of chronic diseases Microbiome-based personalized medicine holds immense potential in the treatment of chronic diseases. Each individual's microbiome is unique, closely linked to their health status, lifestyle habits, and environmental factors in composition and function. By deeply analyzing and understanding an individual's microbiome characteristics, tailored precision treatment strategies can be developed (Tajik et al., 2020). In the treatment of chronic diseases, microbiome-based personalized medicine entails customizing treatment plans according to the patient's microbiome features. For example, adjusting the patient's diet, supplementing specific probiotics or prebiotics, or even employing fecal microbiota transplantation can improve or restore the balance of the patient's microbiome, thus achieving the goal of treating the disease (Alpizar-Rodriguez et al., 2019). Compared to traditional "one-size-fits-all" treatments, microbiome-based personalized medicine is more precise and effective. It not only enhances treatment outcomes and reduces unnecessary drug side effects but also lowers the risk of disease recurrence. With the advancement of microbiome research and technological progress, microbiome-based personalized medicine will become a critical direction in the future treatment of chronic diseases. 3.3 Drug development related to the microbiome and practical cases in the treatment of chronic diseases Currently, drug development related to the microbiome is still in its early stages, but there are practical cases of microbiome-related drug development in the treatment of chronic diseases. Specifically, certain drugs may exert their effects by inhibiting the growth of harmful bacteria or promoting the proliferation of beneficial bacteria. They may also influence the host's physiological processes by modulating metabolites produced by the microbiome, such as short-chain fatty acids (Jack et al., 2018). Additionally, research is exploring the use of specific microbes or their metabolites from the microbiome to develop new drugs or treatment methods.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==